# OXY-101 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/oxy-101

> OXY-101, sponsored by XORTX Therapeutics Inc. (XRTX): 3 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | OXY-101 |
| Codes | OXY-101 |
| Sponsor | XORTX Therapeutics Inc. (XRTX) https://sec-api.dev/companies/xrtx/catalysts |
| Indications |  |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### July 13, 2022: topline data readout

- Status: completed, positive. Date confidence: exact.
- First seen 2025-04-01, last confirmed 2025-05-12.
- Press release filed with the SEC (EX-99) (accession 0001171843-25-001931): "On July 13, 2022, the Company announced positive topline results from Part 1 of the three-part (now four part) XRX-OXY-101 PK Clinical Trial showing a substantial increase in oral bioavailability of two versions of XORTX's proprietary oxypurinol formulation compared to a control formulation." https://www.sec.gov/Archives/edgar/data/1729214/000117184325001931/exh_991.htm
- SEC Form 10-K (accession 0001410578-25-001183): "On July 13, 2022, the Company announced positive topline results from Part 1 of the three-part (now four part) XRX-OXY-101 PK Clinical Trial showing a substantial increase in oral bioavailability of two versions of XORTX's proprietary oxypurinol formulation compared to a control formulation." https://www.sec.gov/Archives/edgar/data/1729214/000141057825001183/tmb-20241231x20f.htm

### August 22, 2022: topline data readout

- Status: completed, positive. Date confidence: exact.
- First seen 2025-04-01, last confirmed 2025-05-12.
- Press release filed with the SEC (EX-99) (accession 0001171843-25-001931): "On August 22, 2022, the Company announced positive topline results from its XRX-OXY-101 PK Clinical Trial - Part 2 showing a substantial increase in oral bioavailability of XORLOTM provided with food compared to the fasted state." https://www.sec.gov/Archives/edgar/data/1729214/000117184325001931/exh_991.htm
- SEC Form 10-K (accession 0001410578-25-001183): "On August 22, 2022, the Company announced positive topline results from its XRX-OXY-101 PK Clinical Trial - Part 2 showing a substantial increase in oral bioavailability of XORLOTM provided with food compared to the fasted state." https://www.sec.gov/Archives/edgar/data/1729214/000141057825001183/tmb-20241231x20f.htm

### January 19, 2023: topline data readout

- Status: completed, positive. Date confidence: exact.
- First seen 2025-04-01, last confirmed 2026-03-20.
- Press release filed with the SEC (EX-99) (accession 0001171843-25-001931): "On January 19, 2023, the Company announced positive topline results from the XRX-OXY-101 - Bridging Pharmacokinetics Clinical Trial (the "Study") characterizing the pharmacokinetics of the" https://www.sec.gov/Archives/edgar/data/1729214/000117184325001931/exh_991.htm
- SEC Form 10-K (accession 0001104659-26-032775): "On January 19, 2023, the Company announced positive topline results from the XRX-OXY-101 - Bridging Pharmacokinetics Clinical Trial characterizing the pharmacokinetics of the Company's proprietary formulation of oral oxypurinol, XORLOTM." https://www.sec.gov/Archives/edgar/data/1729214/000110465926032775/tmb-20251231x20f.htm
- SEC Form 10-K (accession 0001410578-25-001183): "On January 19, 2023, the Company announced positive topline results from the XRX-OXY-101 - Bridging Pharmacokinetics Clinical Trial characterizing the pharmacokinetics of the Company's proprietary formulation of oral oxypurinol, XORLOTM." https://www.sec.gov/Archives/edgar/data/1729214/000141057825001183/tmb-20241231x20f.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/oxy-101.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "OXY-101 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/oxy-101

```bibtex
@misc{secapidev_pdufa_oxy_101_20261116,
  title        = {OXY-101 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/oxy-101}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_oxy_101_20261116","title":"OXY-101 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/oxy-101","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
